GNRH1 and polycystic ovary syndrome: Studies have indicated that the application of GnRH agonist protocol causes mid-cycle gonadotropine flares and ovarian hyperstimulation syndrome (OHSS), which is more observed in women with poly-cystic ovarian syndrome (PCOs).